Clinical Trial Update: Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib with pembrolizumab as first-line therapy for advanced hepatocellular carcinoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Washington | Conditions: Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-04-05